Medicenna Therapeutics Corp (MDNA TO) stock market data APIs
C$1.052
0(0%)
as of September 15, 2025
Try our APIs with
free plan!
Medicenna Therapeutics Corp Financial Data Overview
Price chart is built with
Anychart
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a tumor-targeting and activatable masked anti-PD-1-IL-2 BiSKITTM for cancer; and MDNA132, an IL-13 Superkine for various tumors. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
Prev. Close
1.052
Open
1.0568
High
1.0568
Low
1.0179
52 wk Range
0.78-2.62
Market Cap
87 580 K
Shares Outstanding
83 410 K
EPS
-0.06
Beta
1.79
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Medicenna Therapeutics Corp data using free add-ons & libraries
Get Medicenna Therapeutics Corp Fundamental Data
Medicenna Therapeutics Corp Fundamental data includes:
- Net Revenue:
- EBITDA: -21 841 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-29
- EPS/Forecast: -0.05
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Medicenna Therapeutics Corp News
New
Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream
MIAMI, May 21, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Conference on May 21 & 22, 2025. The Emerg...
Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream
MIAMI, May 20, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Conference on May 21 & 22, 2025. The Emerg...
3 TSX Growth Companies With High Insider Ownership Growing Revenues At 10%
In the wake of a decisive U.S. election outcome, Canadian markets have been influenced by the potential policy shifts south of the border, with fundamental conditions remaining favorable for growth. A...
3 TSX Growth Companies With High Insider Ownership And 12% Revenue Growth
In the wake of a decisive U.S. election outcome, the Canadian market has seen renewed optimism, with the TSX reaching multiple record highs this year as investors anticipate potential policy shifts. I...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
